ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Programmed death-ligand 1 (PD-L1) expression on cancer cells suppresses anti-tumor immune responses.
• Understanding the regulation of PD-L1 degradation is crucial for developing effective cancer immunotherapies.
• PD-L1 is a significant therapeutic target in oncology.

Purpose of the Study:

• To identify novel inducers of PD-L1 degradation.
• To elucidate the molecular mechanism regulating PD-L1 degradation.
• To explore the therapeutic potential of targeting PD-L1 degradation pathways.

Main Methods:

• High-throughput drug screening to identify PD-L1 degradation inducers.
• Investigating the role of EGFR inhibitors in PD-L1 ubiquitination and proteasomal degradation.
• Identifying the specific E3 ubiquitin ligase responsible for PD-L1 targeting.
• Evaluating the impact of ARIH1 overexpression on tumor growth and T cell activation in vivo.
• Assessing the combined effects of EGFR inhibitors and anti-CTLA4 immunotherapy.

Main Results:

• Several compounds were identified as potent inducers of PD-L1 degradation.
• EGFR inhibitors promote PD-L1 ubiquitination and degradation via GSK3α-mediated phosphorylation (Ser279/Ser283).
• ARIH1 was identified as the E3 ubiquitin ligase mediating PD-L1 degradation.
• ARIH1 overexpression suppressed tumor growth and enhanced cytotoxic T cell activation in immunocompetent mice.
• Combination therapy with an EGFR inhibitor (ES-072) and anti-CTLA4 immunotherapy showed additive anti-tumor effects.

Conclusions:

• A novel mechanism for PD-L1 degradation involving EGFR-GSK3α-ARIH1 signaling was delineated.
• This pathway is critical for cancer cells to evade immune surveillance.
• GSK3α and ARIH1 represent promising therapeutic targets for enhancing anti-tumor immunity and improving cancer immunotherapy efficacy.